Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Amanta Healthcare IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 1994 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size 88.2 Cr
Profile
Price Range 120  to  126 per share
Profile
Min Investment ₹126
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

We are a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterileliquid products - parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal (“ABFS”)and Injection Strech Blow Moulding (“ISBM”) technology. Parenteral products can be useful in cases wherepatients cannot intake drug through oral route or drugs are not suitable for oral intake. Additionally, these productsallow rapid absorption of the drug, thereby providing fast action. Furthermore, parenteral routes are better suitedfor drugs which have poor absorption in the gastrointestinal tract or are destroyed by digestive secretions. (Source:CRISIL Report) We manufacture large volume parenterals (“LVPs”) and small volume parenterals (“SVPs”) insix therapeutic segments. In addition to that, we also manufacturer medical devices. We manufacture fluid therapy- (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segmentand products like irrigation, first-aid solution, eye lubricants etc. in medical device segment. We offer wide rangeof closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume rangingfrom 2ml to 1000 ml. Read More

Basic Info

Face Value 10 per share

Price 120  to  126 per share

P/E (x) 34.1

Sales( Cr.) 275

PAT( Cr.) 11

EPS 3.7

Draft Prospectus

Exchange BSE-NSE

Promoter

Company Promoters

Bhavesh Patel Vishal Patel Jayshreeben Patel Jitendrakumar Patel Milcent Appliances Pvt Ltd.

Pre Issue Share Holding 61.53%

Post Issue Share Holding --%

Listing Details:

Listing Price: 134

Listing Gain: 5.97%

Current Price: 125.5

Gain On Issue: 125.5 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Sep 01, 2025
Closing Date Sep 03, 2025
Allotment Sep 04, 2025
Refund Sep 05, 2025
Delivery of Shares Sep 05, 2025
Listing Date Sep 08, 2025

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 119 14,994
Retail (Max) 13 1547 194,922
S-HNI (Min) 14 1666 209,916
S-HNI (Max) 66 7854 989,604
B-HNI (Min) 67 7973 1,004,598

Objective of the Issue

1. Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat 2. Funding capital expenditure requirements towards purchase of equipment, plant and machinery for setting up new manufacturing line for Small Volume Parenteral (“SVP”) at Hariyala, Kheda, Gujarat 3. General corporate purposes.

Issue

Category Nos Bid Bid (x)
QIB 2000000 71722490 35.9x
NII 1500000 314135486 209.4x
Retail 3500000 192422762 55x
EMP 0 0 0x
Total 7000000 578280738 82.6x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Amanta Healthcare Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 175 203 211 192 185 184 171 225 259 280 275
Other Income 1 2 1 2 2 2 1 1 5 1 1
Total Income 176 204 212 194 187 187 172 226 265 282 276
Total Expenditure 139 161 160 145 144 147 133 172 208 223 215
Operating Profit 37 43 52 49 43 40 39 54 56 59 61
Interest 12 14 12 20 41 38 40 44 35 34 28
Depreciation 12 14 15 16 17 16 17 17 18 20 18
Exceptional Income / Expenses 0 0 -0 0 0 0 0 69 0 0 0
Profit Before Tax 13 15 25 12 -14 -15 -18 62 3 5 15
Provision for Tax 12 3 2 1 4 4 4 8 5 2 4
Profit After Tax 1 13 23 11 -19 -19 -22 54 -2 4 11
Adjustments 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 1 13 23 11 -19 -19 -22 54 -2 4 11
Adjusted Earnings Per Share 0.2 3.4 6.3 4.3 -7 -7 -8.1 20.1 -0.8 1.4 3.6

Amanta Healthcare Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 169 192 215 67 48 29 7 65 63 66 96
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 38 42 32 200 196 192 158 176 176 149 132
Other Non-Current Liabilities 33 37 40 49 74 93 104 27 38 35 42
Total Current Liabilities 99 97 102 90 85 73 123 112 97 105 118
Total Liabilities 338 369 390 406 403 388 392 379 374 355 389
Fixed Assets 235 246 262 267 247 244 242 241 238 228 217
Other Non-Current Assets 14 28 26 33 41 39 20 6 5 6 31
Total Current Assets 90 95 102 107 115 105 131 133 131 121 141
Total Assets 338 369 390 406 403 388 392 379 374 355 389

Amanta Healthcare Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 1 1 1 0 3 9 1 0 6 0 2
Cash Flow from Operating Activities 25 40 40 25 32 38 33 64 43 58 47
Cash Flow from Investing Activities -37 -36 -21 -175 -5 -11 -17 -5 -7 -10 -24
Cash Flow from Financing Activities 11 -3 -20 152 -21 -35 -17 -52 -42 -46 -23
Net Cash Inflow / Outflow -0 0 -0 2 6 -8 -0 6 -6 1 -1
Closing Cash & Cash Equivalent 1 1 0 3 9 1 1 6 0 2 0

Amanta Healthcare Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.15 3.44 6.3 4.26 -6.99 -7.04 -8.14 20.08 -0.79 1.35 3.64
CEPS(Rs) 3.58 7.18 10.27 10.43 -0.82 -0.89 -1.79 26.52 6.05 8.71 10.02
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 34.05 40.02 46.32 24.98 17.88 10.85 2.71 24.22 23.44 24.71 33.43
Core EBITDA Margin(%) 19.08 19.22 22.8 23.91 22.13 20.27 22.38 23.79 19.64 20.51 21.72
EBIT Margin(%) 13.16 13.57 16.61 16.61 14.1 12.48 13.06 46.89 14.65 13.92 15.53
Pre Tax Margin(%) 6.8 7.08 11.15 6.39 -7.84 -8.2 -10.37 27.41 1.04 1.92 5.35
PAT Margin (%) 0.29 5.88 10.3 5.84 -10.14 -10.24 -12.75 23.9 -0.81 1.3 3.82
Cash Profit Margin (%) 6.95 12.28 16.8 14.32 -1.19 -1.29 -2.81 31.56 6.27 8.33 10.52
ROA(%) 0.17 3.57 6.1 2.85 -4.64 -4.78 -5.6 13.97 -0.56 1 2.82
ROE(%) 0.44 9.33 14.59 9.57 -32.75 -48.98 -120.09 149.18 -3.3 5.63 12.91
ROCE(%) 9.83 10.63 12.69 10.33 8.44 8.27 8.91 39.99 13.43 14.19 15.16
Receivable days 71.51 78.91 91.57 108.35 104.95 103.45 110.55 77.95 69.3 66.24 65.27
Inventory Days 64.67 56.98 48.15 59.15 71.29 76.92 102.89 103.89 98.61 83.57 87.98
Payable days 150.89 132.35 150.3 170.71 139.77 112.43 157.26 290.83 223.28 158.77 175.62
PER(x) 0 0 0 0 0 0 0 0 0 0 0
Price/Book(x) 0 0 0 0 0 0 0 0 0 0 0
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.97 0.84 0.78 1.43 1.42 1.37 1.47 1.06 0.92 0.81 0.8
EV/Core EBITDA(x) 4.57 3.96 3.14 5.64 6.16 6.37 6.41 4.39 4.24 3.88 3.61
Net Sales Growth(%) 5.89 15.92 4.15 -9.29 -3.49 -0.27 -7.09 31.61 14.94 8.19 -2.01
EBIT Growth(%) -25.66 18.52 28 -13.77 -19.09 -11.7 -2.75 372.38 -64.09 2.81 9.3
PAT Growth(%) -96.38 2198.89 83.3 -51.06 -265.41 -0.69 -15.68 346.78 -103.92 272.14 189.02
EPS Growth(%) -96.38 2169.67 83.3 -32.41 -264.16 -0.69 -15.68 346.78 -103.92 272.14 168.97
Debt/Equity(x) 0.56 0.49 0.4 3.83 5.18 7.94 32.3 3.41 3.43 3.1 2.02
Current Ratio(x) 0.91 0.97 1 1.18 1.35 1.43 1.06 1.19 1.35 1.15 1.19
Quick Ratio(x) 0.54 0.66 0.71 0.81 0.9 0.9 0.6 0.55 0.64 0.59 0.57
Interest Cover(x) 2.07 2.09 3.04 1.63 0.64 0.6 0.56 2.41 1.08 1.16 1.53
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -2% 7% 8% 5%
Operating Profit CAGR 3% 4% 9% 5%
PAT CAGR 175% -41% 0% 27%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 13% 5% 9% -0%
ROCE Average 15% 14% 18% 14%

Company Contact Information

Amanta Healthcare Ltd.

Nikhita Dinodia

079 67777600

cs@amanta.co.in

8th Floor, Shaligram Corporates C. J. Marg Ambli

IPO Lead Manager(s)

Amanta Healthcare Ltd.

Beeline Capital Advisors Pvt Ltd.

Registrar Info

Amanta Healthcare Ltd.

MUFG Intime India Pvt Ltd.

C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai (Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra

+91 810 811 8484

91-022-49186060

rnt.helpdesk@in.mpms.mufg.com

https://in.mpms.mufg.com/

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!